Replimune Group (NASDAQ:REPL) Trading Up 3.7%

Replimune Group, Inc. (NASDAQ:REPL) shares were up 3.7% during trading on Friday . The stock traded as high as $8.25 and last traded at $8.16. Approximately 163,231 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 1,276,234 shares. The stock had previously closed at $7.87.

Wall Street Analyst Weigh In

Several analysts have commented on REPL shares. HC Wainwright lifted their price target on Replimune Group from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, June 7th. Barclays boosted their target price on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Replimune Group in a report on Thursday, June 6th.

Replimune Group Stock Up 8.0 %

The firm has a 50-day moving average of $6.72 and a 200 day moving average of $7.56. The stock has a market capitalization of $522.03 million, a price-to-earnings ratio of -2.62 and a beta of 1.15. The company has a current ratio of 10.72, a quick ratio of 10.72 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, May 16th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. On average, sell-side analysts anticipate that Replimune Group, Inc. will post -3.31 earnings per share for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the completion of the sale, the insider now directly owns 117,131 shares of the company’s stock, valued at $878,482.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, COO Colin Love sold 17,615 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares of the company’s stock, valued at $5,029,422.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $7.50, for a total value of $119,107.50. Following the completion of the transaction, the insider now directly owns 117,131 shares in the company, valued at $878,482.50. The disclosure for this sale can be found here. Insiders sold 107,598 shares of company stock worth $712,516 over the last three months. Corporate insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in REPL. Charles Schwab Investment Management Inc. boosted its stake in Replimune Group by 32.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 378,310 shares of the company’s stock valued at $6,473,000 after purchasing an additional 93,364 shares during the period. Citigroup Inc. lifted its position in shares of Replimune Group by 48.7% in the 3rd quarter. Citigroup Inc. now owns 79,527 shares of the company’s stock worth $1,361,000 after acquiring an additional 26,059 shares during the period. Hsbc Holdings PLC lifted its position in shares of Replimune Group by 45.3% in the 3rd quarter. Hsbc Holdings PLC now owns 19,718 shares of the company’s stock worth $325,000 after acquiring an additional 6,144 shares during the period. Profund Advisors LLC lifted its position in shares of Replimune Group by 19.0% in the 3rd quarter. Profund Advisors LLC now owns 31,557 shares of the company’s stock worth $540,000 after acquiring an additional 5,045 shares during the period. Finally, Alps Advisors Inc. lifted its position in shares of Replimune Group by 2.6% in the 3rd quarter. Alps Advisors Inc. now owns 43,550 shares of the company’s stock worth $745,000 after acquiring an additional 1,083 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.